Partnering, licensing, and collaboration are essential to our business and the end-goal of all our commercialization efforts. We depend on these activities to create lasting and growing value from our proven innovation. To this end Micropharma has focused significant resources to build a team, process, and company to make these relationships successful.
Micropharma is always interested in building new relationships, growing existing ones, and working with interested, qualified investors who would like be part of our growing company.
February 24, 2014
Micropharma's cholesterol lowering probiotic Lactobacillus reuteri NCIMB 30242 was chosen as one of three finalists for the NutrAward for Best New Ingredient of 2014. Now in its 16th year, the NutrAward recognizes and rewards ingredient suppliers that have ingredients with scientific merit, efficacy, market potential, safety, innovation and the ability to increase market credibility. This year's NutrAward finalists were culled from scores of ingredient nominations and more than 100 entrants by our juried panel of industry experts, scientists and nutritionists.
February 06, 2014
A new study, "Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets," published in the January issue of Nutrition Reviews, examined 26 clinical studies and two meta-analyses to assess the potential of probiotics in reducing LDL-cholesterol. Of the probiotics examined, L. reuteri NCIMB 30242 (Cardioviva?) was found to best meet therapeutic lifestyle change (TLC) dietary requirements by: 1. Significantly reducing LDL (bad) cholesterol and total cholesterol, with robustness similar to that of existing TLC dietary options, 2. Improving other coronary heart disease risk factors, such as inflammatory biomarkers, and 3. Having "generally recognized as safe" (GRAS) status.